Liquid Biospy for Urinary Cancers

Launched by IRCCS SAN RAFFAELE · Oct 30, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Liquid Biospy for Urinary Cancers," is studying a type of bladder cancer called urothelial carcinoma. The goal is to understand how certain cells in the blood, known as circulating tumor cells (CTCs), can help doctors predict how a patient’s cancer might behave. Specifically, the trial aims to improve the way patients with non-muscle invasive bladder cancer are assessed after their first surgery to remove the tumor and to identify specific markers in these CTCs that could provide more information about the cancer.

To participate in the trial, individuals must have a diagnosis of urothelial neoplasia (a type of bladder cancer) and should not have received any prior treatment for this condition. The trial is open to all genders and is currently recruiting participants. Those who join can expect to contribute to important research that could improve how bladder cancer is diagnosed and treated in the future. It's a chance to help advance medical knowledge while receiving careful monitoring throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of urothelial neoplasia, naive for therapy
• Exclusion Criteria:
• • Absence of previous neolpastic disease or genetic diseases